Trial reportBMC oral health2024
The effect of esketamine combined with sufentanil based patient-controlled intravenous analgesia for postoperative pain in patients undergoing third molar surgery and maxillofacial trauma: a randomized clinical trial.
Trial report in BMC oral health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effect of Subanesthetic Doses of Esketamine on Early Postoperative Pain Sensitivity in Patients Undergoing Salpingectomy: A Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- Esketamine-based PCIA combined with intercostal nerve block for acute pain after lobectomy: a randomized controlled trial.Frontiers in pharmacology · 2026Trial
- The Effect of Oral Magnesium Supplement on Postoperative Pain Following Mandibular Third Molar Surgery: A Split-Mouth Randomized Placebo-Controlled Trial.Pain research & management · 2025Trial
- Effect of Esketamine Compared with Sufentanil Combined with Propofol in Patients Undergoing First Trimester Surgical Abortion: A Randomized, Double-Blinded Clinical Trial.Drug design, development and therapy · 2025Trial
- Physicochemical stability of sufentanil and esketamine containing analgesic mixtures applied for patient-controlled intravenous analgesia.BMC anesthesiology · 2026Article
- Response to "Methodological Caveats in Evaluating Perioperative Esketamine for Postoperative Pain Sensitivity: A Comment on the Study by Chen et al" [Response to Letter].Drug design, development and therapy · 2026Article
- Systematic Review on Antidepressant Use and Bleeding Risk After Dental Extractions: Evidence Gaps and Clinical Implications.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to investigate the effects of combining esketamine with sufentanil for postoperative patient-controlled intravenous analgesia (PCIA) in patients undergoing elective impacted tooth surgery or open reduction and internal fixation.
methodsIn this single-center, prospective, double-blinded, randomized, parallel-controlled trial, 91 patients were randomly divided into two groups. The experimental group (group ES, n = 46) received a combination of sufentanil 1.5 µg/kg and esketamine 1.0 mg/kg, while the control group (group S, n = 45) received sufentanil 2 µg/kg alone for PCIA after surgery. Primary outcome was assessed using the Visual Analogue Scale (VAS) for patients at rest and during mouth opening at 6 h, 12 h, 24 h, and 48 h post-surgery. Secondary outcomes included the Ramsay Sedation Scale (RSS) scores, the Quality of Recovery-15 (QoR-15) scores, patient satisfaction with analgesia, and the occurrence of adverse events within 48 h post-surgery. The frequency of PCIA button presses and the number of patients requiring rescue analgesia were also recorded.
resultsThe resting VAS scores and the mouth-opening VAS scores at 6 h, 12 h, 24 h, and 48 h post-surgery were significantly lower in Group ES than in Group S (P < 0.05). Additionally, the RSS scores were significantly higher at 6 h (P = 0.032) and 12 h (P = 0.021) post-surgery in Group ES. The frequency of PCIA postoperative use within 48 h post-surgery decreased (P = 0.021) in Group ES, while satisfaction with analgesia and QoR-15 scores increased (P = 0.001 and P < 0.001, respectively). The incidences of postoperative dizziness and nausea/vomiting reduced (P = 0.045 and P = 0.036, respectively) in Group ES, but one adverse event of nightmare was observed. There was no significant difference in rescue analgesia between the two groups.
conclusionThe use of esketamine combined with sufentanil in patients undergoing third molar surgery and maxillofacial trauma can alleviate short-term postoperative pain, and improve the quality of postoperative recovery. Esketamine is worth promoting in the clinical application of oral and maxillofacial surgery.
trial registrationThe study was retrospectively registered in chictr.org.cn with the identifier: ChiCTR2400086662 on 08/07/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.